Andrei Damian, MD
Cardiovascular Disease · Phoenix, AZNPI 1679579346
Payments from drug & device makers
Across 360 payments — averaging $22.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$1K
- Johnson & Johnson$981
- Abbott$704
- Pfizer$629
- Medtronic$560
- Biosense Webster, Inc.$357
- plus $4K from 34 others
What the payments were for
- Food & beverage$8,08498%
- Education$1652%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 110 | $1,462 |
| Johnson & Johnson(2 entities) | 69 | $981 |
| Abbott | 16 | $704 |
| Pfizer | 35 | $629 |
| Medtronic | 10 | $560 |
| Biosense Webster, Inc. | 3 | $357 |
| Bardy Diagnostics, Inc. | 11 | $320 |
| Biotronik Inc. | 3 | $293 |
| Atricure, Inc. | 8 | $274 |
| AstraZeneca | 11 | $274 |
| Heartflow, Inc. | 3 | $254 |
| E.r. Squibb & Sons, L.L.C. | 14 | $249 |
| Amgen | 10 | $182 |
| Cleerly, Inc. | 1 | $180 |
| ZOLL Respicardia, Inc. | 2 | $176 |
| Edwards Lifesciences | 3 | $174 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $163 |
| Boston Scientific | 5 | $150 |
| Boehringer Ingelheim | 6 | $121 |
| Tactile Systems Technology Inc | 1 | $115 |
| Novo Nordisk | 5 | $95 |
| Esperion Therapeutics, Inc. | 4 | $68 |
| Actelion Pharmaceuticals US, Inc. | 2 | $52 |
| Chiesi USA, Inc. | 3 | $51 |
| Merck | 3 | $47 |
| Astellas Pharma US Inc | 2 | $43 |
| Impulse Dynamics (USA) Inc. | 2 | $38 |
| CSL Behring | 2 | $33 |
| Sanofi-aventis U.S. LLC | 2 | $26 |
| Amarin Pharma, Inc. | 1 | $23 |
| Alnylam Pharmaceuticals Inc. | 1 | $22 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $19 |
| Abiomed | 1 | $18 |
| Lundbeck LLC | 1 | $17 |
| Lexicon Pharmaceuticals, Inc. | 1 | $17 |
| Kestra Medical Technology Services, Inc. | 1 | $16 |
| Bayer | 1 | $15 |
| Lucid Diagnostics Inc. | 1 | $14 |
| Itamar Medical Inc | 1 | $9 |
| Vivaquant Inc, Dba Rhythm Express | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,249 in reported general payments places this provider in the 70th percentile of 423 cardiovascular disease providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 323 | $403,667 |
| XareltoRivaroxaban | 140 | $169,845 |
| EntrestoSacubitril/Valsartan | 39 | $50,347 |
| JardianceEmpagliflozin | 18 | $21,842 |
| Repatha SureclickEvolocumab | 22 | $19,383 |
| Flecainide Acetate | 106 | $6,182 |
| Metoprolol Succinate | 363 | $5,361 |
| Atorvastatin Calcium | 531 | $4,863 |
| Ranolazine ErRanolazine | 53 | $4,418 |
| Carvedilol | 412 | $3,634 |
| Losartan Potassium | 295 | $3,336 |
| EdarbiAzilsartan Medoxomil | 12 | $2,751 |
| Rosuvastatin Calcium | 188 | $2,684 |
| Nebivolol Hcl | 31 | $2,401 |
| Lisinopril | 276 | $2,080 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $629 | $403,667323 claims |
| Johnson & JohnsonXarelto | $981 | $169,845140 claims |
| NovartisEntresto | $1,462 | $50,34739 claims |
| Boehringer IngelheimJardiance | $121 | $21,84218 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 423 cardiovascular disease providers in Arizona.
Other cardiovascular disease in Phoenix
- Ashish GuptaPhoenix$1.2M
- Rajkumar SugumaranPhoenix$957K
- Robert ScottPhoenix$331K
- Julie RosenthalPhoenix$313K
- Tabitha MoePhoenix$256K
- Mehrdad SaririanPhoenix$158K
- Jesse SethiPhoenix$150K
- Adam SabbathPhoenix$109K
- Venkataramanan GangadharanPhoenix$97K
- Namit RohantPhoenix$83K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.